CTOs on the Move


 
At iA, we partner with our customers to transform pharmacy by deepening the patient-pharmacist relationship, enhancing patient safety and increasing operational efficiency.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.iarx.com
  • 711, Innovation Way
    Johnson City, NY USA 13790
  • Phone: 607.798.9376

Executives

Name Title Contact Details

Similar Companies

Extreme Performance Inc

Extreme Performance Inc is a Littleton, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Provident Research

Provident Research is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NeuraLace Medical

Relieve Pain, Restore Hope And Reimagine Your Life. Axon Therapy offers an entirely new way to resolve chronic nerve pain. Let us help you return to the life you’ve been missing, on the other side of pain.

Azurity

Azurity Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company focused on the needs of patients, especially children and the elderly, that require customized user-friendly drug formations. Our products have benefited millions of patients whose needs are not served by other commercially available therapies. AZURITY VALUES: COMPASSION - We put the needs of our patients and caregivers at the center of everything we do, including the decisions we make. QUALITY - We aim to provide our patients with the highest-quality, safe, and effective therapies for their needs. INNOVATION - We use the best science and manufacturing techniques to deliver cost-effective, high-value medications to our patients. A COMPANY OF DIFFERENCE MAKERS As Azurity grows to meet new challenges, and serve new patient groups, one thing never changes: our dedication to the lives of others. Whether through our innovative medications, our focus on creating a positive company environment, or our community and volunteer work, we are committed to having a positive impact on the lives of those we touch.

Pathalys

Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end stage kidney disease (ESKD). Pathalys` initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys is headquartered in Research Triangle Park, North Carolina.